点击图片查看原图
份 库存999份
| 货号： | WL0171 |
| 抗体名： | DR5 抗体 |
| 抗体英文名： | DR5 antibody |
| 浓度： | >1mg/ml |
| 应用范围： | WB,IHC |
| 宿主： | 兔 |
| 适应物种： | H,M,R |
| 标记物： | 无 |
| 克隆性： | 否 |
| 保存条件： | -20℃ |
| 形态： | 液体 |
| 亚型： | IgG |
| 规格： | 50μl(>50μg) |
| 产品货号 | WL0171 | |||
| 产品名称 | DR5 Antibody | |||
| 预测分子量 | 55kDa | |||
| 别名 | CD262; KILLER; TRAILR2; TRICK2; TRICKB; ZTNFR9 | |||
| 浓度 | >1 mg/ml | |||
| 免疫原 | 合成DR5多肽 | |||
| 抗体来源 | 兔 | |||
| 特异性 | 抗人、小鼠、大鼠 | |||
| 克隆类型 | 多克隆抗体 | |||
| 产品应用 | WB; IHC | |||
| 成分 | 亲和纯化抗体，20 mM PBS，150 mM NaCl，100 μg/ml BSA，50%甘油，NaN3<0.02% | |||
| 保存条件 | -20℃保存 | |||
| 背景资料 | DR5 is a receptor for TNF-related apoptosis inducing ligand (TRAIL), which has been been shown to induce apoptosis in variety of cell types and has been targeted for cancer therapy. Structurally, DR5 contains an amino-terminal leader cleavage site followed by an extracellular region containing two cysteine-rich repeats, then a central transmembrane domain and a carboxy-terminal death domain. DR5 is expressed in a wide variety of tissues and is transcriptional target for p53. It induces apoptosis through a FADD-dependent pathway. Deletion of DR5 leads to resistance in TRAIL-mediated apoptosis as well as an abrogated response to DNA-damaging stimuli. | |||
更多优惠抗体产品请登录www.wanleibio.cn
温馨提示：不可用于临床治疗。
[VIP第1年] 指数:3
通过沈阳市浑南区市场监督管理局认证 
